Research News

Intensive cholesterol control in high risk patients can reduce cardiovascular events by 20%

BMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j4040 (Published 29 August 2017) Cite this as: BMJ 2017;358:j4040
  1. Susan Mayor
  1. London

Reducing cholesterol to very low levels by treating high risk patients with a statin as well as a proprotein convertase subtilisin-kexin type 9 (PSCK9) inhibitor is associated with a 20% reduction in cardiovascular events, a secondary analysis of a randomised study has reported.1

“Our findings demonstrate that there is essentially no floor effect, and that lower levels translated to a greater reduction in risk,” said lead author Robert Giugliano, from the Brigham and Women’s Hospital in Boston, US. He added, “Among …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe